JP2021534757A5 - - Google Patents

Info

Publication number
JP2021534757A5
JP2021534757A5 JP2021509865A JP2021509865A JP2021534757A5 JP 2021534757 A5 JP2021534757 A5 JP 2021534757A5 JP 2021509865 A JP2021509865 A JP 2021509865A JP 2021509865 A JP2021509865 A JP 2021509865A JP 2021534757 A5 JP2021534757 A5 JP 2021534757A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
amino acid
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509865A
Other languages
English (en)
Japanese (ja)
Other versions
JP7713880B2 (ja
JP2021534757A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047330 external-priority patent/WO2020041361A1/en
Publication of JP2021534757A publication Critical patent/JP2021534757A/ja
Publication of JP2021534757A5 publication Critical patent/JP2021534757A5/ja
Priority to JP2025044879A priority Critical patent/JP2025118591A/ja
Application granted granted Critical
Publication of JP7713880B2 publication Critical patent/JP7713880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509865A 2018-08-20 2019-08-20 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド Active JP7713880B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025044879A JP2025118591A (ja) 2018-08-20 2025-03-19 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765284P 2018-08-20 2018-08-20
US62/765,284 2018-08-20
PCT/US2019/047330 WO2020041361A1 (en) 2018-08-20 2019-08-20 Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025044879A Division JP2025118591A (ja) 2018-08-20 2025-03-19 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド

Publications (3)

Publication Number Publication Date
JP2021534757A JP2021534757A (ja) 2021-12-16
JP2021534757A5 true JP2021534757A5 (cg-RX-API-DMAC7.html) 2022-10-25
JP7713880B2 JP7713880B2 (ja) 2025-07-28

Family

ID=69591189

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021509865A Active JP7713880B2 (ja) 2018-08-20 2019-08-20 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド
JP2025044879A Pending JP2025118591A (ja) 2018-08-20 2025-03-19 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025044879A Pending JP2025118591A (ja) 2018-08-20 2025-03-19 アンタゴニスト性抗腫瘍壊死因子受容体スーパーファミリーポリペプチド

Country Status (8)

Country Link
US (2) US12624117B2 (cg-RX-API-DMAC7.html)
EP (1) EP3840782A4 (cg-RX-API-DMAC7.html)
JP (2) JP7713880B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260004528A (cg-RX-API-DMAC7.html)
CN (1) CN112955179A (cg-RX-API-DMAC7.html)
AU (1) AU2019324134B2 (cg-RX-API-DMAC7.html)
CA (1) CA3109954A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020041361A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション T制御性細胞の増殖または枯渇方法
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
AU2016286108B2 (en) 2015-06-30 2021-03-11 Pfizer Inc. BTLA fusion protein agonists and uses thereof
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
KR20250007678A (ko) 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
WO2020041361A1 (en) * 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
EP3880711A4 (en) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
WO2021231922A1 (en) * 2020-05-14 2021-11-18 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
JP7895285B2 (ja) 2020-06-12 2026-07-27 ナンチン リーズ バイオラブス カンパニー,リミティド Tnfr2に結合する抗体およびその用途
IL299235A (en) * 2020-07-02 2023-02-01 Biolojic Design Ltd Antibodies against (TNFR2) and their uses
CN112159818B (zh) * 2020-08-20 2023-02-21 山东兴瑞生物科技有限公司 用于治疗hcc的核酸、其制备方法、具有该核酸的car-t细胞及细胞的制备方法
EP4281482A4 (en) * 2021-01-21 2025-04-30 The General Hospital Corporation ANTAGONIST ANTIBODIES OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
US20250043015A1 (en) * 2021-06-30 2025-02-06 Shenghe (China) Biopharmaceutical Co., Ltd. Anti-tnfr2 single domain antibody, and preparation method therefor and application thereof
CN116334768A (zh) * 2022-07-14 2023-06-27 上海肽盛医药有限公司 一种结构多样的多肽库及其构建方法和应用
WO2024219994A1 (ru) * 2023-04-16 2024-10-24 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Экспрессионный вектор на основе аденовируса человека 19 серотипа и способ его применения
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309418A (en) 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
SE8204382L (sv) 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5288852A (en) 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3423234A1 (de) 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
WO1986003751A2 (en) 1984-12-21 1986-07-03 Biogen N.V. Purification, production and use of tumor necrosis factors
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US5059530A (en) 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US4985241A (en) 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5370870A (en) 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6984380B1 (en) 1991-08-02 2006-01-10 Denise L. Faustman Treatment of diseases involving faulty MHC class I antigen complex presentation
WO1993002690A1 (en) 1991-08-02 1993-02-18 The General Hospital Corporation Diagnosis and treatment of autoimmune diseases
US5139481A (en) 1991-08-07 1992-08-18 The General Hospital Corporation Treatment for type II diabetes
US5843425A (en) 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
ES2168273T3 (es) 1992-04-23 2002-06-16 Sloan Kettering Inst Cancer Ligando para el receptor c-kit y metodos de uso del mismo.
US5939532A (en) 1993-09-07 1999-08-17 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies to ganglioside GM2
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5560908A (en) 1993-01-22 1996-10-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
WO1997008328A1 (en) 1995-08-30 1997-03-06 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Selective elimination of t cells that recognize specific preselected targets
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5874306A (en) 1996-12-12 1999-02-23 The Regents Of The University Of California Culturing human pancreatic endocrine cells in medium containing extracellular matrix from human bladder carcinoma cells
AU6241698A (en) 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Tace-like and matrilysin-like polypeptides
WO1999029343A1 (en) 1997-12-09 1999-06-17 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6284879B1 (en) 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6165737A (en) 1998-04-16 2000-12-26 The University Of Texas System Board Of Regents DNA fragmentation factor involved in apoptosis
EP1077724A2 (en) 1998-04-17 2001-02-28 The University Of Vermont Methods and products related to metabolic interactions in disease
WO1999059632A1 (en) 1998-05-18 1999-11-25 Applied Research Systems Ars Holding N.V. Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions
US7485293B1 (en) 1999-02-18 2009-02-03 Faustman Denise L Method for inhibiting transplant rejection
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
JP3589912B2 (ja) 1999-09-03 2004-11-17 泰久 福井 ホスファチジルイノシトール−3,4−二リン酸を認識するモノクローナル抗体
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
WO2001044472A1 (en) 1999-12-16 2001-06-21 Amgen, Inc. Tnfr/opg-like molecules and uses thereof
US6414218B1 (en) 2000-01-18 2002-07-02 The General Hospital Corporation Mouse model for rheumatoid arthritis
AU2001266604A1 (en) 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US20020160502A1 (en) 2000-09-26 2002-10-31 Roger Williams Hospital Recombinant BCG vaccines for the prevention and treatment of cancer
US20040031066A9 (en) 2001-01-18 2004-02-12 Faustman Denise L. Mouse model for rheumatoid arthritis
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
JP4596916B2 (ja) 2002-09-05 2010-12-15 メディミューン,エルエルシー Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
CN1771055A (zh) * 2002-09-05 2006-05-10 免疫医疗公司 通过施用cd2拮抗剂预防或治疗t细胞恶性肿瘤的方法
US20040229785A1 (en) 2002-11-15 2004-11-18 Denise Faustman Screening methods to identify treatments for autoimmune disease
US7510877B2 (en) 2003-09-26 2009-03-31 The Regents Of The University Of Michigan Hematopoietic stem cell identification and isolation
JPWO2005035578A1 (ja) 2003-10-09 2007-11-22 協和醗酵工業株式会社 ガングリオシドgm2に特異的に結合する抗体組成物
EP1707627B1 (en) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Antagonistic anti-CD40 antibody mutant
US8563308B2 (en) 2004-03-10 2013-10-22 The Rockefeller University Culture-expanded T suppressor cells and methods of use thereof
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN101084014A (zh) 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
US20080102054A1 (en) 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
CA2605253C (en) 2005-04-11 2017-06-13 Yale University Selective modulation of tumour necrosis factor receptors in therapy
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2107115A1 (en) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
JP2010531138A (ja) 2007-06-13 2010-09-24 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 制御性t細胞ならびに同製造および使用方法
US8900816B2 (en) 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
WO2009129538A2 (en) 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
JP5822822B2 (ja) 2009-04-17 2015-11-24 ニューヨーク ユニバーシティ Tnfファミリー受容体を標的とし、tnf作用を拮抗するペプチド、その組成物、方法および使用
WO2010124262A1 (en) 2009-04-24 2010-10-28 Allostera Pharma Inc. Methods of identification of allosteramers and uses thereof
KR20120005460A (ko) 2009-04-28 2012-01-16 베링거 인겔하임 인터내셔날 게엠베하 Pkc-세타 억제제를 사용하는 면역학적 장애의 생체외 치료
US8530392B2 (en) 2009-05-13 2013-09-10 Shionogi & Co., Ltd. Test agent for visceral obesity and use thereof
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
WO2011107989A1 (en) 2010-03-01 2011-09-09 Lostam Biopharmaceuticals Ltd Improved therapeutic antibodies against flagellated pseudomonas aeruginosa
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
KR101871008B1 (ko) 2010-09-16 2018-06-25 발리오팜 아게 항-huTNFR1 항체
WO2012058137A2 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Methods for diversifying antibodies, antibodies derived therefrom and uses thereof
EP2468764A1 (en) 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants
WO2012122464A1 (en) 2011-03-10 2012-09-13 New York University Methods and compositions for modulating tnf/tnfr signaling
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2013165982A2 (en) 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-human cytomegalvirus antibodies and use thereof
US9531457B2 (en) 2012-07-18 2016-12-27 Kyocera Corporation Interference management of device-to-device communication in a cellular communication system
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション T制御性細胞の増殖または枯渇方法
CN107172880B (zh) 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
EP3180087B1 (en) 2014-08-12 2019-03-13 Alligator Bioscience AB Combination therapies with anti cd40 antibodies
US9172855B1 (en) 2014-08-28 2015-10-27 Avigilon Corporation Pendant housing for a camera
WO2016094309A1 (en) * 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
KR20250007678A (ko) * 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
SG10201912556VA (en) * 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CA3033665A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
IL307684B2 (en) * 2016-09-29 2025-04-01 Amgen Inc Low viscosity antigen binding proteins and methods for preparing them
JP7054209B2 (ja) 2016-11-21 2022-04-13 国立研究開発法人医薬基盤・健康・栄養研究所 エピトープ均質化抗体パネル、ならびにその作製方法および利用
AU2017384528A1 (en) * 2016-12-19 2019-07-04 Ichnos Sciences SA Novel TNFR agonists and uses thereof
WO2019094559A2 (en) 2017-11-09 2019-05-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
WO2020041361A1 (en) 2018-08-20 2020-02-27 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
EP3880711A4 (en) 2018-11-15 2022-12-28 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
WO2021231922A1 (en) 2020-05-14 2021-11-18 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides

Similar Documents

Publication Publication Date Title
JP2025118591A5 (cg-RX-API-DMAC7.html)
FI3447075T3 (fi) Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita
JP6187257B2 (ja) 癌の治療及び/又は予防用医薬組成物
JP6187255B2 (ja) 癌の治療及び/又は予防用医薬組成物
JP2020103301A5 (cg-RX-API-DMAC7.html)
JP2010532169A5 (cg-RX-API-DMAC7.html)
JP2020517591A (ja) 抗cd33抗体剤
JP2013502913A5 (cg-RX-API-DMAC7.html)
JP2022520998A5 (cg-RX-API-DMAC7.html)
JP2019523630A5 (cg-RX-API-DMAC7.html)
JP2014527814A5 (cg-RX-API-DMAC7.html)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2021510736A5 (cg-RX-API-DMAC7.html)
CN112955179A (zh) 拮抗性抗肿瘤坏死因子受体超家族多肽
JP6933724B2 (ja) Nk細胞活性化融合タンパク質、nk細胞およびそれらを含む医薬組成物
US20250074980A1 (en) Humanized and Affinity-Matured Anti-CEACAM1 Antibodies
JP2024515560A5 (cg-RX-API-DMAC7.html)
US20250388682A1 (en) Degradation of egfr using a bispecific binding agent
KR20250169224A (ko) 암의 치료를 위한 항체, 또는 그의 항원-결합 단편의 조합물 및 그의 조성물
CN113038939A (zh) 损害内施用pd-1抑制剂用于治疗皮肤癌
JP2023525991A5 (cg-RX-API-DMAC7.html)
TW202021597A (zh) 具有hpv e6 專一性及pd-1阻斷雙功能之經改造t細胞
WO2021244553A1 (zh) 一种抗pd-l1和egfr的四价双特异性抗体
WO2026037330A1 (en) Antibodies binding to cd3 and uses thereof
KR20250004624A (ko) T 세포 및 nk 세포 인게이저